Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers/Epidemiology/Outcomes

Genitourinary (Prostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy.

Thomas Steuber

5073

Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC).

Santosh Gupta

5065

Analysis of the association between the toll-like receptors 2 and 9 and the emotional status of the elderly cancer patient.

Letícia telles Sales

e17074

Association of changes in the B-cell receptor (BCR) repertoire with overall survival after sipuleucel-T (sip-T) treatment for prostate cancer.

Li Zhang

5072

Association of high CD8+ tumor infiltrating lymphocytes at prostatectomy with improved survival of prostate cancer patients.

Yuanquan Yang

5068

Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC).

Sophia Li

e17056

Association of undetectable PSA with time to metastasis and survival after short-course androgen deprivation therapy for biochemically-recurrent prostate cancer patients.

Evan Y. Yu

e17073

Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).

Anuradha Jayaram

5067

Clinical utility of androgen-receptor splice variant 7 (AR-V7) determinations in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Danilo Piana

e17067

Comparison of healthcare resource use and treatment among prostate cancer patients with and without DNA damage repair gene mutations.

Jinan Liu

e17059

Correlating whole blood AR-V7 and AR-V9 with therapy response to AR-targeted therapies in metastatic castrate-resistant prostate cancer (mCRPC).

Edmond Michael Kwan

e17070

Decreased PSA nadir as a result of dose-escalated stereotactic body radiation for patients with low- and intermediate-risk prostate cancer.

Zaker Hamid Rana

e17076

Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer.

Gillian Rae Vandekerkhove

e17072

Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

Leszek Kotula

5061

Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.

Yu Jen Jan

e17063

Early changes in PSA and association with outcomes in mCRPC patients.

Pasquale Rescigno

5063

Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer.

Neal D. Shore

5078

Exploration of the cGAS-STING pathway in prostate cancer.

Emma Reilly

5075

Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).

Tian Zhang

5059

Gene expression differences in cell-free RNA between prostate cancer patients and healthy individuals.

Erwin Grussie

e17077

Germline variant alleles in rs12422149 of SLCO2B1 and response to abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).

Andrew W Hahn

5076

Immunohistochemical evaluation of p53, Ki67, ERG, MYC and PTEN in Gleason pattern 3 prostate cancer: Implication in active surveillance.

Arie Carneiro

e17068

Impact of definitive local therapy (LT) in men with primary small cell (or poorly differentiated neuroendocrine) prostate carcinomas (pSCPC).

Oluchi Oke

e17061

Impact of treatment sequence on the outcomes of metastatic castration resistant prostate cancer patients (mCRPC) with germline BRCA2 mutations: A subanalysis of the PROREPAIR-B study.

Nuria Romero-Laorden

5071

Inflammatory bowel disease and the risk of prostate cancer.

Shilajit Kundu

e17052

Long-term patterns in race-specific, distant metastasis-free survival following radiation treatment for prostate cancer.

Jennifer Cullen

5077

Missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer.

Masaki Shiota

e17051

Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.

Pasquale Rescigno

5064

Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).

Vincenza Conteduca

5074

Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).

Alexander D. Fuld

e17057

Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: Implications for neoadjuvant clinical trial design.

Catherine Handy

5062

Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).

Christoph W. Reuter

e17069

Prostate cancer (PCa) incidence and severity in hypogonadal men treated with testosterone compared to untreated controls: Experience from 6,500 patient-years from a controlled registry study.

Ahmad Haider

5066

Prostate-specific antigen (PSA) measurements' association with metastasis and mortality in patients with nmCRPC (non-metastatic castration resistant prostate cancer).

Sophia Li

e17058

PSA (Prostate-Specific-Antigen) screening to improve outcome in prostate cancer (PC): Reanalysis of the Prostate-Lung-Colorectal-Ovary (PLCO) randomized controlled trial (RCT).

Lulu Zhang

e17064

Regional differences in the utilization of active surveillance in localized prostate cancer.

Nickolas David Scherzer

e17062

Risk of biochemical recurrence (BCR) in prostate cancer (PCa) patients (pts) with perineural invasion (PNI): Systematic review and meta-analysis.

Stephanie Fletcher

e17060

Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

Antoine Thiery Vuillemin

5058

The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: Systematic review and meta-analysis.

Mok Oh

5060

The GENTleMEN study: Genetic testing for men with metastatic prostate cancer in Washington state and beyond.

Heather H. Cheng

TPS5098

The prognostic value of mid-treatment prostate-specific antigen level in patients receiving salvage radiotherapy.

Jason M. Homza

e17055

The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).

Andrew J. Armstrong

5004

Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations.

Steven Yip

5069

Tumor location and symmetry on prostate cancer progression in a racially diverse military cohort.

Jennifer Cullen

e17065

Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.

Maialen Barrero

5070